

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ACEON® safely and effectively. See full prescribing information for ACEON.

ACEON (perindopril erbumine) 2, 4 and 8 mg Tablets
Initial U.S. Approval: 1993

WARNING: AVOID USE IN PREGNANCY
When pregnancy is detected, ACEON should be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury to or death of the developing fetus. (5.4)

----- **INDICATIONS AND USAGE** -----

- ACEON is indicated for the treatment of patients with essential hypertension (1.1)
- ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction (1.2)

----- **DOSAGE AND ADMINISTRATION** -----

Hypertension

- The recommended initial dose is 4 mg once a day. The dosage may be titrated upward until blood pressure, when measured just before the next dose, is controlled or to a maximum of 16 mg per day (2.1)

Stable Coronary Artery Disease

- ACEON should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased, as tolerated, to a maintenance dose of 8 mg once daily (2.2)

----- **DOSAGE FORMS AND STRENGTHS** -----

- Tablets: 2, 4 and 8 mg (3)

----- **CONTRAINDICATIONS** -----

- Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema (4.0, 5.1)

----- **WARNINGS AND PRECAUTIONS** -----

- Watch for anaphylactoid reactions, including angioedema (5.1)
- Monitor renal function during therapy (5.8)
- Assess for hypotension and hyperkalemia (5.2, 5.6)

----- **ADVERSE REACTIONS** -----

- **Hypertension:** Most common adverse events (incidence greater than or equal to 5%) are cough, dizziness and back pain (6.1)
- **Stable Coronary Artery Disease:** Most common adverse events leading to discontinuation were cough, drug intolerance, and hypotension (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Abbott Laboratories at 1-800-354-0026 (ext. 7530) or FDA at 1-800-FDA-1088 or www.FDA.gov/Medwatch.

----- **DRUG INTERACTIONS** -----

- Diuretics: Excessive drop in blood pressure (7.1)
- Potassium-sparing diuretics/potassium supplements: Hyperkalemia (7.2)
- Lithium: Increase serum lithium levels, symptoms of lithium toxicity (7.3)
- Injectable gold: Nitritoid reactions (facial flushing, nausea, vomiting, and hypotension) (7.4)
- NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.7)

----- **USE IN SPECIFIC POPULATIONS** -----

- Geriatrics: Start at low daily dose (4 mg or less) and titrate slowly as needed. Experience with doses exceeding 8 mg is limited (8.5)
- Dosage adjustment may be necessary in renally impaired patients (8.7)

SEE 17 FOR PATIENT COUNSELING INFORMATION.

Revised: 06/2011

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: AVOID USE IN PREGNANCY

1 INDICATIONS AND USAGE

- 1.1 Hypertension
- 1.2 Stable Coronary Artery Disease

2 DOSAGE AND ADMINISTRATION

- 2.1 Hypertension
- 2.2 Stable Coronary Artery Disease
- 2.3 Dose Adjustment in Renal Impairment and Dialysis

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Anaphylactoid and Possibly Related Reactions
- 5.2 Hypotension
- 5.3 Neutropenia and Agranulocytosis
- 5.4 Fetal/Neonatal Morbidity and Mortality
- 5.5 Impaired Renal Function
- 5.6 Hyperkalemia
- 5.7 Cough
- 5.8 Hepatic Failure
- 5.9 Surgery/Anesthesia

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience
- 6.3 Clinical Laboratory Test Findings

7 DRUG INTERACTIONS

- 7.1 Diuretics
- 7.2 Potassium Supplements and Potassium-Sparing Diuretics
- 7.3 Lithium

- 7.4 Gold
- 7.5 Digoxin
- 7.6 Gentamicin
- 7.7 Non-Steroidal Anti-inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Hypertension
- 14.2 Stable Coronary Artery Disease

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

1
2
3

FULL PRESCRIBING INFORMATION

WARNING: AVOID USE IN PREGNANCY

When pregnancy is detected, discontinue ACEON as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury to or death of the developing fetus (5.4)

4

1 INDICATIONS AND USAGE

5

1.1 Hypertension

6 ACEON is indicated for the treatment of patients with essential hypertension. ACEON may be used alone or given with other classes of
7 antihypertensives, especially thiazide diuretics.

8

1.2 Stable Coronary Artery Disease

9 ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal
10 myocardial infarction. ACEON can be used with conventional treatment for management of coronary artery disease, such as antiplatelet,
11 antihypertensive or lipid-lowering therapy.

12

2 DOSAGE AND ADMINISTRATION

13

2.1 Hypertension

14 *Use in Uncomplicated Hypertensive Patients:* In patients with essential hypertension, the recommended initial dose is 4 mg once a day.
15 The dose may be titrated, as needed to a maximum of 16 mg per day. The usual maintenance dose range is 4 mg to 8 mg administered as a single
16 daily dose or in two divided doses.

17 *Use in Elderly Patients:* The recommended initial daily dosage of ACEON for the elderly is 4 mg daily, given in one or two divided doses.
18 Experience with ACEON is limited in the elderly at doses exceeding 8 mg. Dosages above 8 mg should be administered with careful blood
19 pressure monitoring and dose titration [see *Use in Specific Populations* (8.5)].

20 *Use with Diuretics:* In patients who are currently being treated with a diuretic, symptomatic hypotension can occur following the initial dose of
21 ACEON. Consider reducing the dose of diuretic prior to starting ACEON [see *Drug Interactions* (7.1)].

22

2.2 Stable Coronary Artery Disease

23 In patients with stable coronary artery disease, ACEON should be given at an initial dose of 4 mg once daily for 2 weeks, and then
24 increased as tolerated, to a maintenance dose of 8 mg once daily. In elderly patients (greater than 70 years), ACEON should be given as a 2 mg
25 dose once daily in the first week, followed by 4 mg once daily in the second week and 8 mg once daily for maintenance dose if tolerated.

26

2.3 Dose Adjustment in Renal Impairment and Dialysis

27 Perindoprilat elimination is decreased in renally impaired patients. ACEON is not recommended in patients with creatinine clearance <30
28 mL/min. For patients with lesser degrees of impairment, the initial dosage should be 2 mg/day and dosage should not exceed 8 mg/day. During
29 dialysis, perindopril is removed with the same clearance as in patients with normal renal function.

30

3 DOSAGE FORMS AND STRENGTHS

31 Tablets are oblong with a score on one side.

32 2 mg tablet is white and debossed on the unscored side with "ACN 2".

33 4 mg tablet is pink and debossed on the unscored side with "ACN 4".

34 8 mg tablet is salmon and debossed on the unscored side with "ACN 8".

35

4 CONTRAINDICATIONS

36 ACEON is contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor.
37 ACEON is also contraindicated in patients with hereditary or idiopathic angioedema.

38

5 WARNINGS AND PRECAUTIONS

39

5.1 Anaphylactoid and Possibly Related Reactions

40 Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including
41 endogenous bradykinin, patients receiving ACE inhibitors (including ACEON) may be subject to a variety of adverse events, some of them
42 serious. Black patients receiving ACE inhibitors have a higher incidence of angioedema compared to nonblacks.

43 *Head and Neck Angioedema:* Angioedema of the face, extremities, lips, tongue, glottis, or larynx has been reported in patients treated with
44 ACE inhibitors, including ACEON (0.1% of patients treated with ACEON in U.S. clinical trials). Angioedema associated with involvement of the
45 tongue, glottis or larynx may be fatal. In such cases, discontinue ACEON treatment immediately and observe until the swelling disappears. When
46 involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, administer appropriate therapy, such as subcutaneous
47 epinephrine solution 1:1000 (0.3 to 0.5 mL), promptly.

48 **Intestinal Angioedema:** Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with
49 abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were
50 normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after
51 stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with
52 abdominal pain.

53 **5.2 Hypotension**

54 ACEON can cause symptomatic hypotension. ACEON has been associated with hypotension in 0.3% of uncomplicated hypertensive
55 patients in U.S. placebo-controlled trials. Symptoms related to orthostatic hypotension were reported in another 0.8% of patients.

56 Symptomatic hypotension is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic
57 therapy, dietary salt restriction, dialysis, diarrhea or vomiting [*see Dosage and Administration (2.1)*].

58 ACE inhibitors may cause excessive hypotension, and may be associated with oliguria or azotemia, and rarely with acute renal failure and
59 death. In patients with ischemic heart disease or cerebrovascular disease, an excessive fall in blood pressure could result in a myocardial
60 infarction or a cerebrovascular accident.

61 In patients at risk of excessive hypotension, ACEON therapy should be started under very close medical supervision. Patients should be
62 followed closely for the first two weeks of treatment and whenever the dose of ACEON and/or diuretic is increased.

63 If excessive hypotension occurs, the patient should be placed immediately in a supine position and, if necessary, treated with an
64 intravenous infusion of physiological saline. ACEON treatment can usually be continued following restoration of volume and blood pressure.

65 **5.3 Neutropenia/Agranulocytosis**

66 ACE inhibitors have been associated with agranulocytosis and bone marrow depression, most frequently in patients with renal impairment,
67 especially patients with a collagen vascular disease such as systemic lupus erythematosus or scleroderma.

68 **5.4 Fetal/Neonatal Morbidity and Mortality**

69 ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been
70 reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.

71 The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury,
72 including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure and death. Oligohydramnios has also been
73 reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb
74 contractures, craniofacial deformation and hypoplastic lung development.

75 Prematurity, intrauterine growth retardation, patent ductus arteriosus, and other structural cardiac malformations, as well as neurologic
76 malformations, have been reported following exposure to ACE inhibitors during the first trimester of pregnancy.

77 When patients become pregnant, healthcare providers should make every effort to discontinue the use of ACEON as soon as possible.
78 Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the
79 mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intra-
80 amniotic environment.

81 If oligohydramnios is observed, ACEON should be discontinued unless it is considered life-saving for the mother. Contraction stress
82 testing (CST), a non-stress test (NST) or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and
83 healthcare providers should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

84 Infants with histories of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria and hyperkalemia. If
85 oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be
86 required as a means of reversing hypotension and/or substituting for disordered renal function. Perindopril, which crosses the placenta, can
87 theoretically be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the
88 treatment of these infants.

89 **5.5 Impaired Renal Function**

90 As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible
91 individuals. Renal function should be monitored periodically in patients receiving ACEON. [*see Dosage and Administration (2.3)*].

92 In patients with severe congestive heart failure, where renal function may depend on the activity of the renin-angiotensin-aldosterone
93 system, treatment with ACE inhibitors, including ACEON, may be associated with oliguria, progressive azotemia, and, rarely, acute renal failure
94 and death.

95 In hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur;
96 usually reversible upon discontinuation of the ACE inhibitor. In such patients, renal function should be monitored during the first few weeks of
97 therapy.

98 Some ACEON-treated patients have developed minor and transient increases in blood urea nitrogen and serum creatinine especially in
99 those concomitantly treated with a diuretic.

100 **5.6 Hyperkalemia**

101 Elevations of serum potassium have been observed in some patients treated with ACE inhibitors, including ACEON. Most cases were
102 isolated single values that did not appear clinically relevant and were rarely a cause for withdrawal. Risk factors for the development of

103 hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium
104 supplements and/or potassium-containing salt substitutes [see *Drug Interactions (7.2)*].

105 Serum potassium should be monitored periodically in patients receiving ACEON.

106 **5.7 Cough**

107 Presumably because of the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with
108 all ACE inhibitors, generally resolving after discontinuation of therapy. Consider ACE inhibitor-induced cough in the differential diagnosis of
109 cough.

110 **5.8 Hepatic Failure**

111 Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic
112 necrosis and sometimes death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or
113 marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

114 **5.9 Surgery/Anesthesia**

115 In patients undergoing surgery or during anesthesia with agents that produce hypotension, ACEON may block angiotensin II formation
116 that would otherwise occur secondary to compensatory renin release. Hypotension attributable to this mechanism can be corrected by volume
117 expansion.

118 **6 ADVERSE REACTIONS**

119 Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be
120 directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

121 **6.1 Clinical Trials Experience**

122 The following adverse reactions are discussed elsewhere in labeling:

- 123 • Anaphylactoid reactions, including angioedema [see *Warnings and Precautions (5.1)*]
- 124 • Hypotension [see *Warnings and Precautions (5.2)*]
- 125 • Neutropenia and agranulocytosis [see *Warnings and Precautions (5.3)*]
- 126 • Impaired renal function [see *Warnings and Precautions (5.5)*]
- 127 • Hyperkalemia [see *Warnings and Precautions (5.6)*]
- 128 • Cough [see *Warnings and Precautions (5.7)*]

129 Hypertension

130 ACEON has been evaluated for safety in approximately 3,400 patients with hypertension in U.S. and foreign clinical trials. The data presented
131 here are based on results from the 1,417 ACEON-treated patients who participated in the U.S. clinical trials. Over 220 of these patients were
132 treated with ACEON for at least one year.

133 In placebo-controlled U.S. clinical trials, the incidence of premature discontinuation of therapy due to adverse events was 6.5% in patients
134 treated with ACEON and 6.7% in patients treated with placebo. The most common causes were cough, headache, asthenia and dizziness.

135 Among 1,012 patients in placebo-controlled U.S. trials, the overall frequency of reported adverse events was similar in patients treated
136 with ACEON and in those treated with placebo (approximately 75% in each group). The only adverse events whose incidence on ACEON was at
137 least 2% greater than on placebo were cough (12% vs. 4.5%) and back pain (5.8% vs. 3.1%).

138 Dizziness was not reported more frequently in the perindopril group (8.2%) than in the placebo group (8.5%), but its likelihood increased
139 with dose, suggesting a causal relationship with perindopril.

140 Stable Coronary Artery Disease

141 Perindopril has been evaluated for safety in EUROPA, a double-blind, placebo-controlled study in 12,218 patients with stable coronary
142 artery disease. The overall rate of discontinuation was about 22% on drug and placebo. The most common medical reasons for discontinuation
143 that were more frequent on perindopril than placebo were cough, drug intolerance and hypotension.

144 **6.2 Postmarketing Experience**

145 Voluntary reports of adverse events in patients taking ACEON that have been received since market introduction and are of unknown
146 causal relationship to ACEON include: cardiac arrest, eosinophilic pneumonitis, neutropenia/agranulocytosis, pancytopenia, anemia (including
147 hemolytic and aplastic), thrombocytopenia, acute renal failure, nephritis, hepatic failure, jaundice (hepatocellular or cholestatic), symptomatic
148 hyponatremia, bullous pemphigoid, pemphigus, acute pancreatitis, falls, psoriasis, exfoliative dermatitis and a syndrome which may include:
149 arthralgia/arthritis, vasculitis, serositis, myalgia, fever, rash or other dermatologic manifestations, a positive antinuclear antibody (ANA),
150 leukocytosis, eosinophilia or an elevated erythrocyte sedimentation rate (ESR).

151 **6.3 Clinical Laboratory Test Findings**

152 **Hematology:** Small decreases in hemoglobin and hematocrit occur frequently in hypertensive patients treated with ACEON, but are rarely of
153 clinical importance. In controlled clinical trials, no patient was discontinued from therapy due to the development of anemia. Leukopenia
154 (including neutropenia) was observed in 0.1% of patients in U.S. clinical trials [see *Warnings and Precautions (5.3)*].

155 **Liver Function Tests:** Elevations in ALT (1.6% ACEON versus 0.9% placebo) and AST (0.5% ACEON versus 0.4% placebo) have been
156 observed in placebo-controlled clinical trials. The elevations were generally mild and transient and resolved after discontinuation of therapy.

157 7 DRUG INTERACTIONS

158 7.1 Diuretics

159 Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after
160 initiation of ACEON therapy. The possibility of hypotensive effects can be minimized by either decreasing the dose of or discontinuing the
161 diuretic or increasing the salt intake prior to initiation of treatment with perindopril. If diuretic therapy cannot be altered, provide close medical
162 supervision with the first dose of ACEON, for at least two hours and until blood pressure has stabilized for another hour [see *Warnings and*
163 *Precautions (5.2)*].

164 The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. The bioavailability of perindoprilat
165 was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.

166 7.2 Potassium Supplements and Potassium-Sparing Diuretics

167 ACEON may increase serum potassium because of its potential to decrease aldosterone production. Use of potassium-sparing diuretics
168 (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin,
169 heparin, cyclosporine and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the
170 patient's serum potassium frequently.

171 7.3 Lithium

172 Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor
173 therapy. Frequent monitoring of serum lithium concentration is recommended. Use of a diuretic may further increase the risk of lithium toxicity.

174 7.4 Gold

175 Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy
176 with injectable gold (sodium aurothiomalate) and concomitant ACE Inhibitor therapy including ACEON.

177 7.5 Digoxin

178 A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON, but an
179 effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.

180 7.6 Gentamicin

181 Animal data have suggested the possibility of interaction between perindopril and gentamicin. However, this has not been investigated in
182 human studies.

183 7.7 Non-Steroidal Anti-inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)

184 In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of
185 NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including perindopril, may result in deterioration of renal function,
186 including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving perindopril
187 and NSAID therapy.

188 The antihypertensive effect of ACE inhibitors, including perindopril, may be attenuated by NSAIDs including selective COX-2 inhibitors.

189 8 USE IN SPECIFIC POPULATIONS

190 8.1 Pregnancy

191 Pregnancy Category D [see *Boxed Warning and Warnings and Precautions (5.4)*]. Radioactivity was detectable in fetuses after
192 administration of ¹⁴C-perindopril to pregnant rats.

193 8.3 Nursing Mothers

194 Milk of lactating rats contained radioactivity following administration of ¹⁴C-perindopril. It is not known whether perindopril is secreted
195 in human milk. Because many drugs are secreted in human milk, caution should be exercised when ACEON is given to nursing mothers.

196 8.4 Pediatric Use

197 Safety and effectiveness of ACEON in pediatric patients have not been established.

198 8.5 Geriatric Use

199 The mean blood pressure effect of perindopril was somewhat smaller in patients over 60 than in younger patients, although the difference
200 was not significant. Plasma concentrations of both perindopril and perindoprilat were increased in elderly patients compared to concentrations
201 in younger patients. No adverse effects were clearly increased in older patients with the exception of dizziness and possibly rash.

202 Start at a low dose and titrate slowly as needed. Monitor for dizziness because of potential for falls.

203 Experience with ACEON in elderly patients at daily doses exceeding 8 mg is limited.

204 8.6 Renal Impairment

205 Dosage adjustment may be necessary in renally impaired patients [see Dosage and Administration (2.3) and Clinical Pharmacology
206 (12.3)].

207 8.7 Hepatic Impairment

208 The bioavailability of perindoprilat is increased in patients with impaired hepatic function [see Clinical Pharmacology (12.3)].

209 10 OVERDOSAGE

210 In animals, doses of perindopril up to 2,500 mg/kg in mice, 3,000 mg/kg in rats and 1,600 mg/kg in dogs were non-lethal. Past experiences
211 were scant but suggested that overdosage with other ACE inhibitors was also fairly well tolerated by humans. The most likely manifestation is
212 hypotension, and treatment should be symptomatic and supportive. Therapy with the ACE inhibitor should be discontinued, and the patient
213 should be observed. Dehydration, electrolyte imbalance and hypotension should be treated by established procedures.

214 Among the reported cases of perindopril overdosage, patients who were known to have ingested a dose of 80 mg to 120 mg required
215 assisted ventilation and circulatory support. One additional patient developed hypothermia, circulatory arrest and died following ingestion of up
216 to 180 mg of perindopril. The intervention for perindopril overdose may require vigorous support.


217 Laboratory determinations of serum levels of perindopril and its metabolites are not widely available, and such determinations have, in any
218 event, no established role in the management of perindopril overdose.

219 No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination
220 of perindopril and its metabolites. Perindopril can be removed by hemodialysis, with clearance of 52 mL/min for perindopril and 67 mL/min for
221 perindoprilat.

222 Angiotensin II could presumably serve as a specific antagonist-antidote in the settling of perindopril overdose, but angiotensin II is
223 essentially unavailable outside of scattered research facilities. Because the hypotensive effect of perindopril is achieved through vasodilation and
224 effective hypovolemia, it is reasonable to treat perindopril overdose by infusion of normal saline solution.

225 11 DESCRIPTION

226 ACEON® (perindopril erbumine) Tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-
227 converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3 α S,7 α S)-1-[(S)-N-[(S)-1-Carboxy-
228 butyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). Its molecular formula is
229 C₁₉H₃₂N₂O₅C₄H₁₁N. Its structural formula is:



230 Perindopril erbumine is a white, crystalline powder with a molecular weight of 368.47 (free acid) or 441.61 (salt form). It is freely soluble
231 in water (60% w/w), alcohol and chloroform.
232

233 Perindopril is the free acid form of perindopril erbumine, is a pro-drug and metabolized *in vivo* by hydrolysis of the ester group to form
234 perindoprilat, the biologically active metabolite.

235 ACEON is available in 2 mg, 4 mg and 8 mg strengths for oral administration. In addition to perindopril erbumine, each tablet contains the
236 following inactive ingredients: colloidal silica (hydrophobic), lactose, magnesium stearate and microcrystalline cellulose. The 4 mg and 8 mg
237 tablets also contain iron oxide.

238 12 CLINICAL PHARMACOLOGY

239 12.1 Mechanism of Action

240 ACEON is a pro-drug for perindoprilat, which inhibits ACE in human subjects and animals. The mechanism through which perindoprilat
241 lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes conversion of the
242 inactive decapeptide, angiotensin I, to the vasoconstrictor, angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor, which stimulates
243 aldosterone secretion by the adrenal cortex, and provides negative feedback on renin secretion. Inhibition of ACE results in decreased plasma

244 angiotensin II, leading to decreased vasoconstriction, increased plasma renin activity and decreased aldosterone secretion. The latter results in
245 diuresis and natriuresis and may be associated with a small increase of serum potassium.

246 ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor
247 peptide, play a role in the therapeutic effects of ACEON remains to be elucidated.

248 While the principal mechanism of perindopril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone
249 system, ACE inhibitors have some effect even in apparent low-renin hypertension. Perindopril has been studied in relatively few black patients,
250 usually a low-renin population, and the average response of diastolic blood pressure to perindopril was about half the response seen in nonblack
251 patients, a finding consistent with previous experience of other ACE inhibitors.

252 12.2 Pharmacodynamics

253 After administration of perindopril, ACE is inhibited in a dose and blood concentration-related fashion, with the maximal inhibition of 80
254 to 90% attained by 8 mg persisting for 10 to 12 hours. Twenty-four hour ACE inhibition is about 60% after these doses. The degree of ACE
255 inhibition achieved by a given dose appears to diminish over time (the ID_{50} increases). The pressor response to an angiotensin I infusion is
256 reduced by perindopril, but this effect is not as persistent as the effect on ACE; there is about 35% inhibition at 24 hours after a 12 mg dose.

257 12.3 Pharmacokinetics

258 **Absorption:** Oral administration of ACEON results in peak plasma concentrations that occur at approximately 1 hour. The absolute oral
259 bioavailability of perindopril is about 75%. Following absorption, approximately 30 to 50% of systemically available perindopril is hydrolyzed to
260 its active metabolite, perindoprilat, which has a mean bioavailability of about 25%. Peak plasma concentrations of perindoprilat are attained 3 to
261 7 hours after perindopril administration. Oral administration of ACEON with food does not significantly lower the rate or extent of perindopril
262 absorption relative to the fasted state. However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced
263 approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. In
264 clinical trials, perindopril was generally administered in a non-fasting state.

265 With 4 mg, 8 mg and 16 mg doses of ACEON, C_{max} and AUC of perindopril and perindoprilat increase in a dose-proportional manner
266 following both single oral dosing and at steady state during a once-a-day multiple dosing regimen.

267 **Distribution:** Approximately 60% of circulating perindopril is bound to plasma proteins, and only 10 to 20% of perindoprilat is bound.
268 Therefore, drug interactions mediated through effects on protein binding are not anticipated.

269 **Metabolism and Elimination:** Following oral administration perindopril exhibits multicompartment pharmacokinetics including a deep tissue
270 compartment (ACE binding sites). The mean half-life of perindopril associated with most of its elimination is approximately 0.8 to 1 hours.

271 Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine. Six
272 metabolites resulting from hydrolysis, glucuronidation and cyclization via dehydration have been identified. These include the active ACE
273 inhibitor, perindoprilat (hydrolyzed perindopril), perindopril and perindoprilat glucuronides, dehydrated perindopril and the diastereoisomers of
274 dehydrated perindoprilat. In humans, hepatic esterase appears to be responsible for the hydrolysis of perindopril.

275 The active metabolite, perindoprilat, also exhibits multicompartment pharmacokinetics following the oral administration of ACEON.
276 Formation of perindoprilat is gradual with peak plasma concentrations occurring between 3 and 7 hours. The subsequent decline in plasma
277 concentration shows an apparent mean half-life of 3 to 10 hours for the majority of the elimination, with a prolonged terminal elimination half-
278 life of 30 to 120 hours resulting from slow dissociation of perindoprilat from plasma/tissue ACE binding sites. During repeated oral once daily
279 dosing with perindopril, perindoprilat accumulates about 1.5- to 2-fold and attains steady state plasma levels in 3 to 6 days. The clearance of
280 perindoprilat and its metabolites is almost exclusively renal.

281 **Elderly:** Plasma concentrations of both perindopril and perindoprilat in elderly patients (greater than 70 years) are approximately twice those
282 observed in younger patients, reflecting both increased conversion of perindopril to perindoprilat and decreased renal excretion of perindoprilat.
283 [see *Dosage and Administration (2.1) and Use In Specific Populations (8.5)*].

284 **Heart Failure:** Perindoprilat clearance is reduced in congestive heart failure patients, resulting in a 40% higher dose interval AUC.

285 **Renal Impairment:** With perindopril doses of 2 mg to 4 mg, perindoprilat AUC increases with decreasing renal function. At creatinine
286 clearances of 30 to 80 mL/min, AUC is about double that at 100 mL/min. When creatinine clearance drops below 30 mL/min, AUC increases
287 more markedly.

288 In a limited number of patients studied, perindopril clearance by dialysis ranged from about 40 to 80 mL/min. Perindoprilat clearance by
289 dialysis ranged from about 40 to 90 mL/min [see *Dosage and Administration (2.3)*].

290 **Hepatic Impairment:** The bioavailability of perindoprilat is increased in patients with impaired hepatic function. Plasma concentrations of
291 perindoprilat in patients with impaired liver function were about 50% higher than those observed in healthy subjects or hypertensive patients
292 with normal liver function.

293 13 NONCLINICAL TOXICOLOGY

294 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

295 **Carcinogenicity:** No evidence of carcinogenic effect was observed in studies in rats and mice when perindopril was administered at dosages
296 up to 20 times (mg/kg) or 2 to 4 times (mg/m²) the maximum proposed clinical doses (16 mg/day) for 104 weeks.

297 **Mutagenesis:** No genotoxic potential was detected for ACEON, perindoprilat and other metabolites in various *in vitro* and *in vivo*
298 investigations, including the Ames test, the *Saccharomyces cerevisiae* D4 test, cultured human lymphocytes, TK ± mouse lymphoma assay,
299 mouse and rat micronucleus tests and Chinese hamster bone marrow assay.

300 **Impairment of Fertility:** There was no meaningful effect on reproductive performance or fertility in the rat given up to 30 times (mg/kg) or 6
301 times (mg/m²) the proposed maximum clinical dosage of ACEON during the period of spermatogenesis in males or oogenesis and gestation in
302 females.

303 14 CLINICAL STUDIES

304 14.1 Hypertension

305 In placebo-controlled studies of perindopril monotherapy (2 mg to 16 mg once daily) in patients with a mean blood pressure of about
306 150/100 mm Hg, 2 mg had little effect, but doses of 4 mg to 16 mg lowered blood pressure. The 8 mg and 16 mg doses were indistinguishable,
307 and both had a greater effect than the 4 mg dose. In these studies, doses of 8 mg and 16 mg per day gave supine, trough blood pressure reductions
308 of 9 to 15/5 to 6 mm Hg. When once daily and twice daily dosing were compared, the twice daily dosing regimen was generally slightly superior,
309 but by not more than about 0.5 mm Hg to 1 mm Hg. After 2 mg to 16 mg doses of perindopril, the trough mean systolic and diastolic blood
310 pressure effects were about 75 to 100% of peak effects.

311 Perindopril's effects on blood pressure were similar when given alone or on a background of 25 mg hydrochlorothiazide. In general, the
312 effect of perindopril occurred promptly, with effects increasing slightly over several weeks.

313 Formal interaction studies of ACEON have not been carried out with antihypertensive agents other than thiazides. Limited experience in
314 controlled and uncontrolled trials coadministering ACEON with a calcium channel blocker, a loop diuretic or triple therapy (beta-blocker,
315 vasodilator and a diuretic), does not suggest any unexpected interactions. In general, ACE inhibitors have less than additive effects when given
316 with beta-adrenergic blockers, presumably because both work in part through the renin-angiotensin system.

317 In uncontrolled studies in patients with insulin-dependent diabetes, perindopril did not appear to affect glycemic control. In long-term use,
318 no effect on urinary protein excretion was seen in these patients.

319 The effectiveness of ACEON was not influenced by sex and it was less effective in black patients than in nonblack patients. In elderly
320 patients (greater than or equal to 60 years), the mean blood pressure effect was somewhat smaller than in younger patients, although the
321 difference was not significant.

322 14.2 Stable Coronary Artery Disease

323 The EUROPEAN trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) was a multicenter,
324 randomized, double-blind and placebo-controlled study conducted in 12,218 patients who had evidence of stable coronary artery disease without
325 clinical heart failure. Patients had evidence of coronary artery disease documented by previous myocardial infarction more than 3 months before
326 screening, coronary revascularization more than 6 months before screening, angiographic evidence of stenosis (at least 70% narrowing of one or
327 more major coronary arteries), or positive stress test in men with a history of chest pain. After a run-in period of 4 weeks during which all patients
328 received perindopril 2 mg to 8 mg, the patients were randomly assigned to perindopril 8 mg once daily (n=6,110) or matching placebo (n=6,108).
329 The mean follow-up was 4.2 years. The study examined the long-term effects of perindopril on time to first event of cardiovascular mortality,
330 nonfatal myocardial infarction, or cardiac arrest in patients with stable coronary artery disease.

331 The mean age of patients was 60 years; 85% were male, 92% were taking platelet inhibitors, 63% were taking β blockers, and 56% were
332 taking lipid-lowering therapy. The EUROPA study showed that perindopril significantly reduced the relative risk for the primary endpoint events
333 (Table 1). This beneficial effect is largely attributable to a reduction in the risk of nonfatal myocardial infarction. This beneficial effect of
334 perindopril on the primary outcome was evident after about one year of treatment (Figure 1). The outcome was similar across all predefined
335 subgroups by age, underlying disease or concomitant medication (Figure 2).

336

Table 1. Primary Endpoint and Relative Risk Reduction


	Perindopril (N = 6,110)	Placebo (N = 6,108)	RRR (95% CI)	P
Combined Endpoint				
Cardiovascular mortality, nonfatal MI or cardiac arrest	488 (8%)	603 (9.9%)	20% (9 to 29)	0.0003
Component Endpoint				
Cardiovascular mortality	215 (3.5%)	249 (4.1%)	14% (-3 to 28)	0.107
Nonfatal MI	295 (4.8%)	378 (6.2%)	22% (10 to 33)	0.001
Cardiac arrest	6 (0.1%)	11 (0.2%)	46% (-47 to 80)	0.22

CI=confidence interval; RRR: relative risk reduction; MI: myocardial infarction

337


Figure 1. Time to First Occurrence of Primary Endpoint

338



339
340

Figure 2. Beneficial Effect of Perindopril Treatment on Primary Endpoint in Predefined Subgroups



341
342

Size of squares proportional to the number of patients in that group. Dashed line indicates overall relative risk.

343 **16 HOW SUPPLIED/STORAGE AND HANDLING**

344 Tablets are oblong with a score on one side.

Tablets	Appearance	NDC (Bottles of 100)
2 mg	White, debossed "ACN 2" on unscored side	NDC 0032-1101-01
4 mg	Pink, debossed "ACN 4" on unscored side	NDC 0032-1102-01
8 mg	Salmon-colored, debossed "ACN 8" on unscored side	NDC 0032-1103-01

345 **Keep out of the reach of children.**

346 Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture.



For further information, please call our medical communications department toll-free 1-800-241-1643.

347 **17 PATIENT COUNSELING INFORMATION**

348 Inform female patients of childbearing age that use of drugs, such as ACEON, that act on the renin-angiotensin system during pregnancy
349 may cause serious problems in the fetus and infant. Patients taking ACEON who are or plan to become pregnant should immediately notify
350 their healthcare provider.

351 Tell patients to report immediately signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, hoarseness
352 or difficulty in swallowing or breathing) and to take no more drug before consulting a healthcare provider.

353 Tell patients to report promptly any indication of infection (*e.g.*, sore throat, fever) which could be a sign of neutropenia.

354 **Manufactured by:**
355 Patheon Pharmaceuticals, Inc.
356 Cincinnati, OH 45237 USA

357 **Marketed by:**
358 Abbott Laboratories
359 North Chicago, IL 60064, U.S.A.

360 © 2011 Abbott Laboratories

361 500063 5E Rev Jun 2011

362

